Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytokinetics Inc.

www.cytokinetics.com

Latest From Cytokinetics Inc.

Pipeline Watch: Phase III Readouts For Talazoparib, Ampion, Avatrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Tecentriq, Viaskin Peanut And Capalizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup

Partnered with Astellas, the San Francisco-area biotech hopes next-generation CK-107 will succeed in a measure of slow vital capacity due to stronger potency and better tolerability compared to tirasemtiv.

Clinical Trials Rare Diseases

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cytokinetics Inc.
  • Senior Management
  • Robert I Blum, Pres. & CEO
    Sharon Barbari, EVP, Fin. & CFO
    Andrew A Wolff, MD, SVP, CMO
    Elisabeth A Schnieders, PhD, SVP, Bus. Dev.
    Scott R Jordan, VP, Commercial Dev.
  • Contact Info
  • Cytokinetics Inc.
    Phone: (650) 624-3000
    280 East Grand Ave.
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register